Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study
[EN] Objective: To better understand drivers of disease progression in non-alcoholic steatohepatitis (NASH), we assessed clinical and sociodemographic markers of fibrosis progression in adults with NASH. Patients and methods: Physician-reported patient demographics and clinical characteristics were...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2024 |
| País: | España |
| Recursos: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositório: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/370616 |
| Acesso em linha: | http://hdl.handle.net/10261/370616 https://api.elsevier.com/content/abstract/scopus_id/85177176517 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Risk factor Advanced fibrosis Biopsia hepática Enfermedad del hígado graso sin alcohol Esteatohepatitis no alcohólica Factor de riesgo Fibrosis avanzada Liver biopsy Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis |
| Resumo: | [EN] Objective: To better understand drivers of disease progression in non-alcoholic steatohepatitis (NASH), we assessed clinical and sociodemographic markers of fibrosis progression in adults with NASH. Patients and methods: Physician-reported patient demographics and clinical characteristics were utilised from the real-world Global Assessment of the Impact of NASH (GAIN) study. Factors associated with likelihood of fibrosis progression since NASH diagnosis were identified using a logistic regression model. Results: Overall, 2349 patients in Europe from the GAIN study were included; mean age was 54.6 years and 41% were women. Significant covariates included age, years since diagnosis, employment status, fibrosis stage at diagnosis, type 2 diabetes mellitus, hypertension, liver transplant and liver biopsy at diagnosis. Risk of progression was 1.16 (95% confidence interval 1.12–1.20; p < 0.001) times higher for each additional year since NASH diagnosis and 5.43 (2.68–11.37; p < 0.001) times higher when physicians proposed a liver transplant at diagnosis. Compared with full-time employed patients, risk of progression was 1.77 (1.19–2.60; p = 0.004) times higher for unemployed patients and 3.16 (1.30–7.63; p = 0.010) times higher for those unable to work due to NASH. Conclusions: Disease duration, NASH severity and presence of other metabolic comorbidities could help to assess risk of progression in patients with NASH. |
|---|